Merck Group
Business & Industry
- AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
- Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor
- ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases
- Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer
- Pfizer enters into exclusive licensing agreement with 3SBio
Research & Development
- Penn engineers turn toxic fungus into anti-cancer compound
- New drug for diabetes and obesity shows promising results
- Article presents innovative drug for controlling weight and blood sugar
- Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes
- Targeting fusion protein's role in childhood leukemia produces striking results
- AI could accelerate protein engineering - key for developing new medicines
- Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy